The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - Volume 2

Journal of Viral Hepatitis

Volumn 22, Issue s1, 2015, Pages 26-45

  Hatzakis, A ^a   Chulanov, V ^b   Gadano, A C ^c   Bergin, C ^d,e   Ben Ari, Z ^f   Mossong, J ^g   Schreter I ^h   Baatarkhuu, O ⁱ   Acharya, S ^j   Aho, I ^k   Anand, A C ^l   Andersson, M I ^m   Arendt, V ⁿ   Arkkila, P ^k   Barclay, K ^p   Bessone, F ^q   Blach, S ^r   Blokhina, N ^s   Brunton, C R ^t   Choudhuri, G ^u   Cisneros, L ^v   Croes, E A ^w   Dahgwahdorj, Y A ⁱ   Dalgard, O ^x   Daruich, J R ^y   Dashdorj, N R ^z   Davaadorj, D ⁱ   De Knegt, R J ^aa   De Vree, M ^ab   Estes, C ^r   Flisiak, R ^ac   Gane, E ^ad   Gower, E ^r   Halota, W ^ae   Henderson, C ^af   Hoffmann, P ^ag   Hornell, J ^p   Houlihan, D ^ah   Hrusovsky, S ^ai,aj   Jarcuska P ^h   Kershenobich, D ^ak   Kostrzewska, K ^al   Kristian, P ^h   Leshno, M ^am   Lurie, Y ^an   Mahomed, A ^ao   Mamonova, N ^ap   Mendez Sanchez, N ^aq   Norris, S ^d   Nurmukhametova, E ^s   Nymadawa, P ^ar   Oltman, M ^as   Oyunbileg, J ^at   Oyunsuren, Ts ^au   Papatheodoridis, G ^a   Pimenov, N ^b   Prabdial Sing, N ^av,aw   Prins, M ^ax,ay   Radke, S ^az,ba   Rakhmanova, A ^bb   Razavi Shearer, K ^r   Reesink, H W ^ay   Ridruejo, E ^bc   Safadi, R ^bd   Sagalova, O ^be   Sanchez Avila, J F ^ak   Sanduijav, R ^at   Saraswat, V ^bf   Seguin Devaux, C ^o   Shah, S R ^bg   Shestakova, I ^bh,bi   Shevaldin, A ^ae   Shibolet, O ^am,bj   Silva, M O ^bk   Sokolov, S ^bl   Sonderup, M ^bm   Souliotis, K ^bn   Spearman, C W ^bo   Staub, T ⁿ   Stedman, C ^bp   Strebkova, E A ^bq   Struck, D ^o   Sypsa, V ^a   Tomasiewicz, K ^br   Undram, L ⁱ   Van Der Meer, A J ^bs   Van Santen, D ^bt   Veldhuijzen, I ^bu   Villamil, F G ^bv   Willemse, S ^ay   Zuckerman, E ^bt   Zuure, F R ^bt   Puri, P ^bs   Razavi, H ^r   more..

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b CENTRAL RESEARCH INSTITUTE OF EPIDEMIOLOGY   (Russian Federation)

^c HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^d ST JAMES S HOSPITAL   (Ireland)

^e TRINITY COLLEGE DUBLIN   (Ireland)

^f SHEBA MEDICAL CENTER   (Israel)

^g LABORATOIRE NATIONAL DE SANTÉ   (Luxembourg)

^h P J AFÁRIK UNIVERSITY   (Slovakia)

ⁱ MONGOLIAN NATIONAL UNIVERSITY OF MEDICAL SCIENCES   (Mongolia)

^j ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^k HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^l INDRAPRASTHA APOLLO HOSPITAL   (India)

^m UNIVERSITY OF STELLENBOSCH   (South Africa)

ⁿ CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

^o LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^p The Hepatitis Foundation of New Zealand   (New Zealand)

^q UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

^r Center for Disease Analysis   (United States)

^s Infectious Diseases Hospital   (Russian Federation)

^t CANTERBURY DISTRICT HEALTH BOARD   (New Zealand)

^u Fortis Memorial Research Institute   (India)

^v INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^w NETHERLANDS INSTITUTE OF MENTAL HEALTH AND ADDICTION   (Netherlands)

^x AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^y HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^z Onom Foundation   (Mongolia)

^aa ERASMUS MEDICAL CENTER   (Netherlands)

^ab UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^ac MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^ad AUCKLAND CITY HOSPITAL   (New Zealand)

^ae University Medical Center Groningen ^*  (Russian Federation)

^af Needle Exchange Programme New Zealand   (New Zealand)

^ag Directorate of Health   (Luxembourg)

^ah ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^ai SLOVAK MEDICAL UNIVERSITY   (Slovakia)

^aj 1st Department of Internal Medicine   (Slovakia)

^ak INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^al HTA CONSULTING   (Poland)

^am TEL AVIV UNIVERSITY   (Israel)

^an SHAARE ZEDEK MEDICAL CENTER   (Israel)

^ao UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^ap Research and Diagnostic Center for Clinical Psychiatry   (Russian Federation)

^aq LIVER RESEARCH UNIT   (Mexico)

^ar Mongolian Academy of Medical Sciences   (Mongolia)

^as Gastroenterology and Hepatology Center   (Slovakia)

^at National Center for Communicable Diseases   (Mongolia)

^au INSTITUTE OF CHEMISTRY AND CHEMICAL TECHNOLOGY   (Mongolia)

^av NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^aw UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^ax DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^ay ACADEMIC MEDICAL CENTER   (Netherlands)

^az INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

^ba UNIVERSITY OF AUCKLAND   (New Zealand)

^bb St Petersburg AIDS Center   (Russian Federation)

^bc CEMIC   (Argentina)

^bd HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^be SOUTH URAL STATE MEDICAL UNIVERSITY   (Russian Federation)

^bf SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^bg Global Hospital   (India)

^bh A I EVDOKIMOV MOSCOW STATE UNIVERSITY OF MEDICINE AND DENTISTRY   (Russian Federation)

^bi N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

^bj TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^bk UNIVERSIDAD AUSTRAL   (Argentina)

^bl Tyumen Regional State Autonomous Healthcare Institution Consulting and Diagnostic Centre   (Russian Federation)

^bm UNIVERSITY OF CAPE TOWN   (South Africa)

^bn UNIVERSITY OF PELOPONNESE   (Greece)

^bo UNIVERSITY OF CAPE TOWN   (South Africa)

^bp UNIVERSITY OF OTAGO   (New Zealand)

^bq SAMARA STATE MEDICAL UNIVERSITY   (Russian Federation)

^br MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^bs ARMY HOSPITAL RESEARCH AND REFERRAL   (India)

^bt TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^bu Public Health Service Rotterdam Rijnmond   (Netherlands)

^bv HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

more..

Author keywords

diagnosis; disease burden; epidemiology; HCV; hepatitis C; incidence; mortality; prevalence; treatment

Indexed keywords

PEGINTERFERON; RIBAVIRIN; ANTIVIRUS AGENT;

ARGENTINA; ARTICLE; DISEASE COURSE; FINLAND; GREECE; HEPATITIS C; HUMAN; INDIA; INFECTION RATE; IRELAND; ISRAEL; LIVER DISEASE; LUXEMBOURG; MEXICO; MONGOLIA; MORBIDITY; MORTALITY; NETHERLANDS; NEW ZEALAND; NORWAY; POLAND; PREVALENCE; REINFECTION; RUSSIAN FEDERATION; SLOVAKIA; SOUTH AFRICA; ADOLESCENT; ADULT; AGED; BIOLOGICAL MODEL; CHILD; COMPARATIVE STUDY; COST OF ILLNESS; FEMALE; HEALTH; HEPATITIS C, CHRONIC; INFANT; MALE; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; COST OF ILLNESS; DISEASE PROGRESSION; FEMALE; GLOBAL HEALTH; HEPATITIS C, CHRONIC; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PREVALENCE; YOUNG ADULT;

EID: 84920270905     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12351     Document Type: Article

References (59)

1. Gower E, Estes C, Hindman S, Razavi-Shearer K, Razavi H,. Global burden and genotype distribution of hepatitis C virus. J Hepatol 2014; Forthcoming.
2. Deuffic-Burban S, Deltenre P, Buti M, et al,. Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology 2012; 143: 974-985.
3. Wedemeyer H, Duberg AS, Buti M, et al,. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat 2014; 21 (Suppl 1): 60-89.
4. Lozano R, Naghavi M, Foreman K, et al,. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-2128.
5. The Kirby Institute for Infection and Immunity in Society. HIV, viral hepatitis and sexually transmissible infections in Australia. Annual Surveillance Reports 1997-2013 [cited: 21 November 2013]. Available at: http://www.kirby.unsw.edu.au/surveillance/Annual-Surveillance-Reports (accessed 11-21-2013).
6. Bosetti C, Levi F, Lucchini F, Zatonski WA, Negri E, La Vecchia C,. Worldwide mortality from cirrhosis: an update to 2002. J Hepatol 2007; 46: 827-839.
7. Deuffic S, Poynard T, Valleron AJ,. Correlation between hepatitis C virus prevalence and hepatocellular carcinoma mortality in Europe. J Viral Hepat 1999; 6: 411-413.
8. Razavi H, Waked I, Sarrazin C, et al,. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 2014; 21 (Suppl 1): 34-59.
9. Razavi H, Elkhoury AC, Elbasha E, et al,. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 2013; 57: 2164-2170.
10. Sypsa V, Touloumi G, Papatheodoridis GV, et al,. Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments. J Viral Hepat 2005; 12: 543-550.
11. Sypsa V, Touloumi G, Tassopoulos NC, et al,. Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection. J Viral Hepat 2004; 11: 366-374.
12. Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB,. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat 2007; 14: 107-115.
13. Deuffic-Burban S, Poynard T, Valleron AJ,. Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model. J Viral Hepat 2002; 9: 114-122.
14. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW,. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-521.
15. Saraswat V, Norris S, Zuckerman E,. Historical epidemiology of hepatitis C virus (HCV) in select countries-volume 2. J Viral Hepat 2014; Forthcoming.
16. Aleman S, Rahbin N, Weiland O, et al,. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin Infect Dis 2013; 57: 230-236.
17. Alter MJ, Margolis HS, Krawczynski K, et al,. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992; 327: 1899-1905.
18. Thomas DL, Seeff LB,. Natural history of hepatitis C. Clin Liver Dis 2005; 9: 383-398.
19. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL,. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999; 29: 908-914.
20. Thein HH, Yi Q, Dore GJ, Krahn MD,. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48: 418-431.
21. Bennett WG, Inoue Y, Beck JR, Wong JB, Pauker SG, Davis GL,. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127: 855-865.
22. Bernfort L, Sennfalt K, Reichard O,. Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden. Scand J Infect Dis 2006; 38: 497-505.
23. Younossi ZM, Singer ME, McHutchison JG, Shermock KM,. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999; 30: 1318-1324.
24. University of California, B, Mack Planck Institute for Demographic Research. Human Mortality Database. 14 June 2013 [cited: 1 February 2013] Available at: www.mortality.org (accessed 02-01-2013).
25. Kershenobich D, Razavi HA, Cooper CL, et al,. Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data. Liver Int 2011; 31 (Suppl 2): 4-17.
26. Engstrom A, Adamsson C, Allebeck P, Rydberg U,. Mortality in patients with substance abuse: a follow-up in Stockholm County, 1973-1984. Int J Addict 1991; 26: 91-106.
27. Frischer M, Goldberg D, Rahman M, Berney L,. Mortality and survival among a cohort of drug injectors in Glasgow, 1982-1994. Addiction 1997; 92: 419-427.
28. Hickman M, Carnwath Z, Madden P, et al,. Drug-related mortality and fatal overdose risk: pilot cohort study of heroin users recruited from specialist drug treatment sites in London. J Urban Health 2003; 80: 274-287.
29. Oppenheimer E, Tobutt C, Taylor C, Andrew T,. Death and survival in a cohort of heroin addicts from London clinics: a 22-year follow-up study. Addiction 1994; 89: 1299-1308.
30. Perucci CA, Davoli M, Rapiti E, Abeni DD, Forastiere F,. Mortality of intravenous drug users in Rome: a cohort study. Am J Public Health 1991; 81: 1307-1310.
31. Bjornaas MA, Bekken AS, Ojlert A, et al,. A 20-year prospective study of mortality and causes of death among hospitalized opioid addicts in Oslo. BMC Psychiatry 2008; 8: 8.
32. Kamper-Jorgensen M, Ahlgren M, Rostgaard K, et al,. Survival after blood transfusion. Transfusion 2008; 48: 2577-2584.
33. Aceijas C, Rhodes T,. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy 2007; 18: 352-358.
34. Nelson PK, Mathers BM, Cowie B, et al,. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: Results of systematic reviews. Lancet 2011; 378: 571-583.
35. Ridruejo E, Adrover R, Cocozzella D, Fernandez N, Reggiardo MV,. Efficacy, tolerability and safety in the treatment of chronic hepatitis C with combination of PEG-Interferon-Ribavirin in daily practice. Ann Hepatol 2010; 9: 46-51.
36. Sari J, Outi L, Ruska RF, et al,. Infectious Diseases in Finland, 2012. Report No. 12. Helsinki, Finland: National Institute for Health and Welfare (THL), 2013.
37. Raptopoulou M, Touloumi G, Tzourmakliotis D, et al,. Significant epidemiological changes in chronic hepatitis C infection: results of the nationwide HEPNET-GREECE cohort study. Hippokratia 2011; 15: 26-31.
38. Reitox National Focal Point. 2012 National Report (2011 Data) to the EMCDDA. Athens, Greece: Greek REITOX Focal Point, 2012.
39. Kumar A, Sharma KA, Gupta RK, Kar P, Chakravarti A,. Prevalence & risk factors for hepatitis C virus among pregnant women. Indian J Med Res 2007; 126: 211-215.
40. Thakral B, Marwaha N, Chawla YK, et al,. Prevalence & significance of hepatitis C virus (HCV) seropositivity in blood donors. Indian J Med Res 2006; 124: 431-438.
41. Thornton L, Murphy N, Jones L, et al,. Determination of the burden of hepatitis C virus infection in Ireland. Epidemiol Infect 2012; 140: 1461-1468.
42. Kerzman H, Green MS, Shinar E,. Risk factors for hepatitis C virus infection among blood donors in Israel: a case-control study between native Israelis and immigrants from the former Soviet Union. Transfusion 2007; 47: 1189-1196.
43. Cornberg M, Razavi HA, Alberti A, et al,. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011; 31 (Suppl 2): 30-60.
44. Roman F, Hawotte K, Struck D, et al,. Hepatitis C virus genotypes distribution and transmission risk factors in Luxembourg from 1991 to 2006. World J Gastroenterol 2008; 14: 1237-1243.
45. Burguete-Garcia AI, Conde-Gonzalez CJ, Jimenez-Mendez R, et al,. Hepatitis C seroprevalence and correlation between viral load and viral genotype among primary care clients in Mexico. Salud Publica Mex 2011; 53 (Suppl 1): S7-S12.
46. Rivas-Estilla AM, Cordero-Perez P, Trujillo-Murillo Kdel C, et al,. Genotyping of hepatitis C virus (HCV) in infected patients from Northeast Mexico. Ann Hepatol 2008; 7: 144-147.
47. Sun CA, Chen HC, Lu CF, et al,. Transmission of hepatitis C virus in Taiwan: prevalence and risk factors based on a nationwide survey. J Med Virol 1999; 59: 290-296.
48. Chaves S, Widdowson MA, Bosman A,. Surveillance of HCV infection in the Netherlands. Euro Surveill 2003; 8: 108-113.
49. Vriend HJ, Van Veen MG, Prins M, et al,. Hepatitis C virus prevalence in the Netherlands: migrants account for most infections. Epidemiol Infect 2013; 141: 1310-1317.
50. Institute of Environmental Science and Research Limited. Notifiable and other diseases in New Zealand: Annual Report 2012. 2013 April 30. Report No.: FW13014.
51. Chlabicz S, Flisiak R, Grzeszczuk A, Kovalchuk O, Prokopowicz D, Chyczewski L,. Known and probable risk factors for hepatitis C infection: a case series in north-eastern Poland. World J Gastroenterol 2006; 12: 141-145.
52. Abdourakhmanov DT, Hasaev AS, Castro FJ, Guardia J,. Epidemiological and clinical aspects of hepatitis C virus infection in the Russian Republic of Daghestan. Eur J Epidemiol 1998; 14: 549-553.
53. Paralicova Z, Kristian P, Schreter I,. [Epidemiological survey of hepatitis C at the Clinic of Infectology and Travel Medicine in Kosice]. Epidemiol Mikrobiol Imunol 2009; 58: 158-162.
54. Wiessing L, Guarita B, Giraudon I, Brummer-Korvenkontio H, Salminen M, Cowan SA,. European monitoring of notifications of hepatitis C virus infection in the general population and among injecting drug users (IDUs)-the need to improve quality and comparability. Euro Surveill 2008; 13: 1-5.
55. Evon DM, Verma A, Dougherty KA, et al,. High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities. Dig Dis Sci 2007; 52: 3251-3258.
56. Morrill JA, Shrestha M, Grant RW,. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med 2005; 20: 754-758.
57. Nesdale A, Baker M, Gane E, et al,. Hepatitis C infection in New Zealand: estimating the current and future prevalence and impact. 2000 July 1.
58. Pokrovsky VI, Zhibrun AB,. (Eds) Viral Hepatitis in Russian Federation. Analytical Review, 9th edn. Saint Petersburg, 2013: 113-114.
59. Gane E, Kershenobich-Stalnikowitz D, Devaux M,. Strategies to manage hepatitis C virus (HCV) infection disease burden-volume 2. J Viral Hepat 2014; Forthcoming.